Most experts agree that 0.5 to 2.0 pounds per week, or roughly 1% of body weight, is appropriate
The full mechanistic argument, including receptor kinetics and pulse-amplitude data, sits in the CJC-1295 vs Ipamorelin individual peptide comparison
Some users report transient fatigue, mild headaches, dizziness, sleep changes, or water retention, particularly during the first 1-2 weeks
GLP-1 receptor agonists are injectable (or oral for semaglutide tablets) and may produce greater weight loss, whilst SGLT2 inhibitors are oral and work by increasing glucose excretion in urine
The drug is suitable for chronic weight management in patients with: Obesity (body max index equal to or greater than 30), or
Regulatory status outside the US varies